The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•28 March 2026•

1 min read

Boston Scientific's EKOS System Shows Superiority in HI-PEITHO Trial Results

Key Facts

1The HI-PEITHO trial demonstrated that the EKOS system plus anticoagulation is superior to anticoagulation alone for treating acute pulmonary embolism.

2The study resulted in a statistically significant reduction in clinical event rates among intermediate-risk patients.

3Findings were published in The New England Journal of Medicine and presented at the ACC.26 conference.

Boston Scientific (BSX) announced positive results from its HI-PEITHO clinical trial, marking a significant milestone for its EKOS Endovascular System. The study demonstrated that the EKOS system, when combined with anticoagulation, is superior to standard anticoagulation therapy alone for treating acute pulmonary embolism. Specifically, the trial showed a statistically significant reduction in clinical event rates among intermediate-risk patients. These findings were published in the prestigious New England Journal of Medicine (NEJM) and presented at the ACC.26 conference. The success of this trial provides strong clinical evidence for catheter-directed therapy as a more effective intervention than traditional medication-only protocols. Market analysts view this development as a boost for Boston Scientific's competitive position in the medical device sector, potentially driving increased adoption and revenue.

Create Free Account